6. パーキンソン病 Parkinson disease Clinical trials / Disease details

臨床試験数 : 2,307 / 薬物数 : 2,007 - (DrugBank : 349) / 標的遺伝子数 : 188 - 標的パスウェイ数 : 199

12 trials found

diseases per page:

Showing 1 to 10 of 12 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04277247 (ClinicalTrials.gov)	January 12, 2021	10/2/2020	Botulinum Toxin Type A for Foot Dystonia-associated Pain in Parkinson's Disease	Botulinum ToxinA (Onabotulinumtoxin A) for Foot Dystonia-associated Pain in Parkinson's Disease: A R ...	Dystonia Disorder;Parkinson Disease	Drug: Botulinum toxin type A;Drug: Placebo	University of Calgary	Allergan	Recruiting	30 Years	100 Years	All	40	Phase 2/Phase 3	Canada
2	ChiCTR-INR-17012013	2017-09-01	2017-07-17	Clinical study of botulinum toxintype A in the treatment of depressive symptoms in patients with Par ...	Clinical study of botulinum toxintype A in the treatment of depressive symptoms in patients with Par ...	Parkinson‘s disease, Depression	BTX-A:BOTOX Allergan;Placebo:0.9% Sodium Chloride Injection;	Shanghai Tongji Hospital, Tongji University	NULL	Pending	18	80	Both	BTX-A:40;Placebo:40;		China
3	NCT02668497 (ClinicalTrials.gov)	March 2016	26/1/2016	Kinematic-based BoNT-A Bilateral Upper Limb PD Therapy	Kinematic Characterization of Upper Limb Parkinson's Disease Tremor for Optimized Botulinum ToxinTyp ...	Parkinson's Disease	Drug: Botulinum Toxin Type A	Western University, Canada	NULL	Active, not recruiting	18 Years	80 Years	All	50	Phase 2	Canada
4	NCT02472210 (ClinicalTrials.gov)	July 2014	11/6/2015	The Use of Botox in Advanced Parkinson's Patients Experiencing Pain	A Study of the Utility of Botulinum ToxinType A for Pain in Advanced Parkinson's Disease Double Blin ...	Parkinson's Disease	Drug: Botulinum Toxin	University Health Network, Toronto	NULL	Active, not recruiting	18 Years	N/A	Both	14	Phase 4	NULL
5	EUCTR2012-005539-10-DE (EUCTR)	29/04/2014	18/12/2013	Clinical study to investigate the efficacy and safety of two dose levels of NT 201 versus placebo in ...	Prospective, randomized, double-blind, placebo-controlled, parallel-group multicenter study, with an ...	Chronic troublesome sialorrhea resulting from neurological conditions in adults with Parkinson's dis ...	Trade Name: Xeomin INN or Proposed INN: NT 101 Other descriptive name: BOTULINUM TOXINTYPE A Trade Name ...	Merz Pharmaceuticals GmbH	NULL	Not Recruiting			Female: yes Male: yes	180	Phase 3	United States;Poland;Germany
6	EUCTR2009-017412-32-IT (EUCTR)	13/12/2011	27/04/2010	RANDOMISED CONTROLLED TRIAL OF BOTULINUM TOXINTYPE A AND B EFFICACY IN REDUCING DROOLING IN PARKINSO ...	RANDOMISED CONTROLLED TRIAL OF BOTULINUM TOXINTYPE A AND B EFFICACY IN REDUCING DROOLING IN PARKINSO ...	Parkinson disease MedDRA version: 9.1;Level: LLT;Classification code 10013363	Trade Name: BOTOX INN or Proposed INN: Botulinum toxin Trade Name: NEUROBLOC INN or Proposed INN: Botul ...	AZIENDA OSPEDALIERO UNIVERSITARIA OSPEDALI RIUNITI UMBERTO I - G.M.LANCISI - G.SALESI	NULL	Not Recruiting			Female: yes Male: yes			Italy
7	NCT02427646 (ClinicalTrials.gov)	October 2011	22/4/2015	Kinematic-guided BoNT-A Treatment for ET and PD Tremor	Use of Kinematic Assessment of Hand Tremor Pre- and Post- Treatment With Botulinum ToxinType A in Es ...	Tremor	Drug: BoNT-A	Western University, Canada	NULL	Active, not recruiting	18 Years	80 Years	All	54	Phase 2	NULL
8	NCT00909883 (ClinicalTrials.gov)	September 2009	19/5/2009	Foot Dystonia Treatment by Botulinum ToxinInjections in Parkinson Disease : Efficiency of Injections ...	Foot Dystonia Treatment by Botulinum ToxinInjections in Parkinson Disease : Efficiency of Injections ...	Parkinson's Disease;Foot Dystonia	Drug: Botulinum Toxin: Xeomin;Drug: Placebo	University Hospital, Clermont-Ferrand	Merz Pharma France	Recruiting	30 Years	75 Years	Both	45	Phase 3	France
9	NCT00767546 (ClinicalTrials.gov)	May 2009	5/10/2008	Botulinum Toxin for Treatment of Seborrhic Dermatitis in Parkinsonian Patients	Botulinum Toxin for Treatment of Seborrhic Dermatitis in Parkinsonian Patients	Parkinson Disease;Parkinsonism;Seborrheic Dermatitis	Drug: Botulinum toxin	Rabin Medical Center	NULL	Not yet recruiting	18 Years	N/A	Both	40	Phase 1	NULL
10	NCT01421719 (ClinicalTrials.gov)	February 2009	19/8/2011	Safety and Efficacy of botulinumA Toxin (BotoxA) for Treatment of Neurogenic Bladder of Parkinson's ...	Onabotulinum Toxin Type A (BTX-A) For Treatment of Neurogenic Overactive Bladder Due to Parkinson's ...	Parkinson's Disease;Neurogenic Bladder;Urinary Incontinence;Clostridium Botulinum ToxinAdverse React ...	Drug: Cystoscopic injection of Botox into the urinary bladder	Stanford University	Allergan	Completed	50 Years	85 Years	All	20	Phase 4	United States

First Previous1 2Next Last